AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
7 Biotech Stocks to Boost Your Portfolio to Peak Health
While innovations such as artificial intelligence have become all the rage, there's another type of technology – biotechnology – that deserves careful consideration for your portfolio. Indeed, if you haven't considered the sector, it's really time to focus on biotech stocks.
AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer
Data from a late-stage study shows that treatment with AstraZeneca's (AZN) Imfinzi plus chemotherapy before and after bladder removal surgery improves survival in patients.
China approves AstraZeneca's Tagrisso-chemo combo as first-line treatment
China has approved the use of AstraZeneca's blockbuster cancer drug Tagrisso in combination with chemotherapy as a first line of treatment for adults with a type of advanced lung cancer, the company said on Wednesday.
AstraZeneca's Oncology Success: Fueling Future Growth
AstraZeneca is becoming a leader in the cancer therapeutics market, which is reflected in the growth of its share price. On June 25, 2024, Tagrisso, in combination with chemotherapy, was approved in Japan as the first-line treatment for people with NSCLC whose tumors have certain mutations. Tagrisso sales were about $1.6 billion in the first three months of 2024, up 12% year-over-year.
AstraZeneca still a buy for one broker despite mixed Imfinzi data
AstraZeneca PLC (LSE:AZN) has put out mixed data for the Phase III trials of its immuno-oncology (IO) drug Imfinzi, notes broker ShoreCap. There was a positive result from the Phase III NIAGARA trial looking at its use perioperatively (either side of surgery) for the treatment of bladder cancer (MIBC).
AstraZeneca disappointed with failure of immunotherapy in early-stage lung cancer
AstraZeneca PLC (LSE:AZN) shared some disappointing news on an advanced lung cancer trial of its Imfinzi immunotherapy. Phase III trials showed the drug did not achieve statistical significance for its primary endpoint of disease-free survival compared to placebo in early-stage non-small cell lung cancer.
BenevolentAI says second target identified by AstraZeneca collaboration
BenevolentAI (OTC:BAIVF) said that AstraZeneca PLC (LSE:AZN) has identified a target for systemic lupus erythematosus (SLE) using the former's artificial intelligence-driven drug discovery platform - the second asset selected as part of a collocation the pair have. Benevolent's tie-up with AZ began in 2019, focusing on idiopathic pulmonary fibrosis and chronic kidney disease.
AstraZeneca says Imfinzi fails in late-stage trial to treat type of lung cancer
AstraZeneca said on Tuesday its blockbuster cancer drug, Imfinzi, failed to improve disease-free survival in a late-stage trial to treat a type of early-stage lung cancer.
3 Undervalued Pharma Stocks to Buy for Dividends and Capital Gains
There are multiple reasons to consider exposure to pharmaceutical stocks for the long-term portfolio. First, pharma stocks have a low-beta and provide and help in reducing the overall beta of a portfolio that's overweight growth stocks.
3 No-Brainer Stocks to Buy for Under $100 Right Now
AstraZeneca should have lots of growth ahead. Bristol Myers Squibb has what it takes to navigate a major patent cliff.
AstraZeneca's (AZN) Truqap Gets EU Nod for Breast Cancer
The European Commission approves AstraZeneca's (AZN) Truqap in combination with Faslodex for ER-positive, HER2-negative advanced or metastatic breast cancer.
